Vical (VICL) – Press Releases
-
Vical Stockholders Approve Reverse Stock Split and Merger with Brickell
-
Hercules Capital Reports Second Quarter 2019 Financial Results
-
Hercules Capital Announces Multiple Portfolio Company Achievements in Q2 2019
-
Vical and Brickell Announce Merger Agreement
-
Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives
-
New Research: Key Drivers of Growth for Interface, USA Truck, Weingarten Realty Investors, Unum Group, Trivago N.V. ADS, and Vical — Factors of Influence, Major Initiatives and Sustained Production
-
Vical Reports Third Quarter 2018 Financial and Operational Results
-
Vical to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
-
Vical Reports Second Quarter 2018 Financial and Operational Results
-
Vical Announces Review of Potential Strategic Transactions
-
Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint
-
Vical Reports First Quarter 2018 Financial and Operational Results
-
Vical Announces News Release and Conference Call Schedule for First Quarter 2018 Financial Results
-
Vical Reports Fourth Quarter 2017 Financial and Operational Results
-
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
-
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
-
Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis
-
Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis
-
Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical Programs
-
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
-
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
-
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
-
Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock
-
Vical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B Infection
-
Vical Reports Third Quarter 2017 Financial and Operational Results
-
Vical Announces News Release and Conference Call Schedule for Third Quarter 2017 Financial Results
-
Vical to Provide Company Update at BIO Investor Forum Conference
-
Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial
-
Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy Trial
-
Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences
-
Vical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
-
Vical Reports Second Quarter 2017 Financial and Operational Results
-
Vical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial Results
-
Vical to Provide Company Update at the 2017 BIO International Convention
-
Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2
-
Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
-
Vical Reports First Quarter 2017 Financial Results
-
Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results
-
Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
-
Vical to Host Virtual Research & Development Day on May 2, 2017
-
Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial
-
Vical to Provide Company Update at the 29th Annual ROTH Conference
-
Vical to Provide Company Update at BIO Asia International Conference
-
Vical Reports Fourth Quarter 2016 Financial Results
-
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2016 Financial Results
-
Vical Provides Company Update at Biocom's Global Life Science Partnering Conference
-
Vical Provides Company Update at BIO CEO and Investor Conference
-
Vical Reports Third Quarter 2016 Financial Results
-
Vical Announces News Release and Conference Call Schedule for Third Quarter 2016 Financial Results
-
Vical Announces Initiation of a Phase 2 Trial of Its HSV-2 Therapeutic DNA Vaccine for Genital Herpes
Back to VICL Stock Lookup
